SGLT2-inhibitors: Should they be considered anti-remodeling drugs?

Eur J Intern Med. 2023 Aug:114:42-44. doi: 10.1016/j.ejim.2023.05.023. Epub 2023 May 22.

Authors

Enrico Fabris¹, Gianfranco Sinagra², Stefan D Anker³

Affiliations

¹ Cardiothoracovascular Department, University of Trieste, Trieste, Italy. Electronic address: enrico.fabris@hotmail.it.
² Cardiothoracovascular Department, University of Trieste, Trieste, Italy.
³ Department of Cardiology (CVK) of German Heart Center Charité, Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.

PMID: 37225594
DOI: 10.1016/j.ejim.2023.05.023

No abstract available

Publication types

Comment

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Humans
Hypoglycemic Agents / therapeutic use
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2
Hypoglycemic Agents